<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04845061</url>
  </required_header>
  <id_info>
    <org_study_id>beta blockers in copd</org_study_id>
    <nct_id>NCT04845061</nct_id>
  </id_info>
  <brief_title>Evaluating the Outcome of Cardio Selective beta1- Blockers Use in Patients With Copd</brief_title>
  <official_title>Evaluating the Outcome of Cardio Selective beta1- Blockers Use in Patients With Chronic Obstructive Pulmonary Disease: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To Evaluate the Outcome of cardio selective beta1 (Î²1-) blockers use in patients with chronic&#xD;
      obstructive pulmonary disease.&#xD;
&#xD;
      Patient education about the COPD and their medications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic obstructive pulmonary disease (COPD) is a common preventable and Treatable airway&#xD;
      disorder characterized by symptoms such as dyspnea, chronic Cough, and sputum production&#xD;
      along with persistent airflow limitation that is not fully Reversible.&#xD;
&#xD;
      Evidence provided by post hoc analysis of clinical trials and large observational studies&#xD;
      suggests a beneficial effect of beta-blockers on mortality and exacerbation in mild to&#xD;
      moderate COPD patients.&#xD;
&#xD;
      Evidence concerning cardio selective B blockers. Over the past 20 years' non selective B&#xD;
      blockers have largely been replaced with cardio selective blockers. Cardio selective beta&#xD;
      blockers such as atenolol and metoprolol are at least 20 times more potent at blocking B-1&#xD;
      receptors than B-2 receptors. At therapeutic doses the B-1 blocking effect, and therefore the&#xD;
      risk of bronco constriction, is negligible. In addition there is strong evidence that&#xD;
      B-blocked cause up-regulation and sensitization of B-receptors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">January 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>forced vital capacity</measure>
    <time_frame>3 months</time_frame>
    <description>amount of air that can be forcibly exhaled from the lung after taking the deepest breath possible (FVC\liter)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>forced expiratory volume in one second</measure>
    <time_frame>3 month</time_frame>
    <description>volume of air exhaled under condition in the first second (FEV1\liter)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>blood pressure</measure>
    <time_frame>3 month</time_frame>
    <description>BP millimetre mercury</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Copd</condition>
  <arm_group>
    <arm_group_label>nebivolol then placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Comprises15 copd patients, after recruitment in study and written informed consent, patient's administered nebivolol (1.25 mg for one week then2.5mg fore another one week and 5 mg at 8am for 10 weeks)and washout period4 weeks then shifted to placebo for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo then nebivolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Contain 15 copd patient's after recruitment and Written informed consent administered placebo for 12 weeks and washout period for 4 weeks then shifted to nebivolol for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebivolol Tablets</intervention_name>
    <description>cardio selective beta-1 blocker</description>
    <arm_group_label>nebivolol then placebo</arm_group_label>
    <arm_group_label>placebo then nebivolol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female.&#xD;
&#xD;
          2. informed consent.&#xD;
&#xD;
          3. Age &gt;40years.&#xD;
&#xD;
          4. FEVl/FVC&lt;70%.&#xD;
&#xD;
          5. diagnosed 3 month before enrollment (mild-moderate)&#xD;
&#xD;
          6. Reversability test pre-post bronchodilators FEVl predicted&lt;200ml/hr and less than 12%.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Asthmatic patient.&#xD;
&#xD;
          2. patient already use B blockers.&#xD;
&#xD;
          3. Acute exacerbation.&#xD;
&#xD;
          4. Pregnency -lactation.&#xD;
&#xD;
          5. Advanced cardiac, renal or liver disease according to investigator opinion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>asma suliman, bachelor</last_name>
    <phone>00201006279989</phone>
    <email>asma.shain2017@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>marwa adel, associated professor</last_name>
    <phone>00201006383120</phone>
    <email>dr.marwa.adel2016@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chest Department, Ain Shams University Hospitals, Cairo, Egypt.</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Chest Department, Ain Shams University Hospitals</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>gamal A-rhahman, professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chest Department, Ain Shams University Hospitals</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>gamal A-rhahman, professor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 29, 2021</study_first_submitted>
  <study_first_submitted_qc>April 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2021</study_first_posted>
  <last_update_submitted>April 10, 2021</last_update_submitted>
  <last_update_submitted_qc>April 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Asma Shain Suliman</investigator_full_name>
    <investigator_title>Clinical pharmacist</investigator_title>
  </responsible_party>
  <keyword>beta blockers -nebivolol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nebivolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

